How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) posted its quarterly earnings data on Sunday, May, 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.05.

What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO?

10 employees have rated Constellation Pharmaceuticals Chief Executive Officer Jigar Raythatha on Glassdoor.com . Jigar Raythatha has an approval rating of 100% among the company's employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD) , AbbVie (ABBV) , Applied Materials (AMAT) , Inovio Pharmaceuticals (INO) , Intel (INTC) , NVIDIA (NVDA) , Pfizer (PFE) , Sorrento Therapeutics (SRNE) , Cisco Systems (CSCO) and AT&T (T) .

When did Constellation Pharmaceuticals IPO?

Constellation Pharmaceuticals (CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

NASDAQ:CNST

Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free CNST Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $33.99
▼
$33.99
50-Day Range: $33.63
▼
$33.99
52-Week Range: $17.00
▼
$39.30

Volume: N/A
Average Volume: 940,325 shs
Market Capitalization: $1.63 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Constellation Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Constellation Pharmaceuticals Stock (NASDAQ:CNST)

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

CNST Stock News Headlines

April 20, 2023 | chron.com

Your guide to Constellation Field, home of the Sugar Land Space Cowboys

March 8, 2023 | forbes.com

Constellation Software

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 15, 2023 | thestreet.com

Constellation Brands Inc. News

December 11, 2022 | cnet.com

Starlink Explained: What You Need to Know About Elon Musk's Satellite Internet Service

January 19, 2022 | bizjournals.com

Former execs at bluebird, Constellation join VC firm Third Rock

See More Headlines

Receive CNST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/09/2021
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CNST
CUSIP: 21036U206
CIK: 29806
Web: www.constellationpharma.com
Phone: 617-714-0555
Fax: N/A
Employees: 154
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-126,360,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -33.12%
Return on Assets: -29.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.39
Quick Ratio: 15.39

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.63 per share
Price / Book: 3.94

Miscellaneous

Outstanding Shares: 47,915,000
Free Float: N/A
Market Cap: $1.63 billion
Optionable: Not Optionable
Beta: 2.59

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Jigar Raythatha
Pres, CEO & Director
Ms. Emma Reeve (Age 60)
Chief Financial Officer
Comp: $562.98k
Dr. Patrick Trojer Ph.D. (Age 48)
Sr. VP & Chief Scientific Officer
Comp: $556.52k
Ms. Karen Higgins Valentine J.D. (Age 49)
Sr. VP, Chief Legal Officer & Gen. Counsel
Comp: $535.93k
Dr. Jeffrey Humphrey M.D. (Age 59)
Chief Medical Officer
Comp: $462.25k
Dr. Danny Reinberg
Co-Founder
Dr. Yang Shi Ph.D.
Co-Founder
Dr. David Allis
Co-Founder
Mr. Mohan Bala Ph.D.
Chief Operating Officer
Mr. Ronald Aldridge (Age 67)
Sr. Director of Investor Relations

Key Competitors

View All Competitors

CNST Stock Analysis - Frequently Asked Questions

How were Constellation Pharmaceuticals' earnings last quarter?: Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) posted its quarterly earnings data on Sunday, May, 9th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.05.
What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO?: 10 employees have rated Constellation Pharmaceuticals Chief Executive Officer Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among the company's employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Constellation Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).
When did Constellation Pharmaceuticals IPO?: Constellation Pharmaceuticals (CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

This page (NASDAQ:CNST) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis

About Constellation Pharmaceuticals Stock (NASDAQ:CNST)

CNST Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CNST Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info